SYNDAX PHARMACEUTICALS Receives ‘Buy’ Rating from Brokerages
October 31, 2023
🌥️Trending News
Syndax Pharmaceuticals ($NASDAQ:SNDX), Inc. recently received an average rating of “Buy” from brokerages. This news sent the company’s stock price surging as investors anticipated positive returns coming from this pharmaceutical company. Syndax Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutics to treat cancer and other serious diseases. Their mission is to identify, develop, and commercialize innovative therapies that improve the lives of patients living with cancer and other diseases such as lung cancer tumors, breast cancer, and prostate cancer.
Their pipeline of drugs includes candidates that are in various stages of clinical development, discovery, and preclinical research. Syndax Pharmaceuticals is committed to developing and commercializing its pipeline of products to improve treatment options for patients living with cancer and other serious diseases. The company has received favorable ratings from brokerages, which suggests that investors should consider buying shares in the company for potential long-term gains.
Stock Price
On Monday, SYNDAX PHARMACEUTICALS had a notable rise in stock prices, opening at $12.5 and closing at $13.0. This marked a 6.2% increase from the previous closing price of 12.3. This increase in stock prices may be attributed to the positive ‘buy’ rating from multiple brokerages.
This is further evidence of the optimism for the company’s future prospects with its current line of products and upcoming developments. Investors also appear to hold a favorable outlook for the company, pushing stock prices to new highs. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Syndax Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -160.34 | 17.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Syndax Pharmaceuticals. More…
| Operations | Investing | Financing |
| -126.04 | -50.6 | 153.78 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Syndax Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 431.34 | 31.3 | 5.81 |
Key Ratios Snapshot
Some of the financial key ratios for Syndax Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 351.6% | – | 19.2% |
| FCF Margin | ROE | ROA |
| 20.8% | -23.7% | -23.0% |
Analysis
At GoodWhale, we conducted a fundamental analysis of SYNDAX PHARMACEUTICALS. Our Star Chart shows that SYNDAX PHARMACEUTICALS is strong in asset, medium in profitability and weak in dividend and growth. We classified it as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. SYNDAX PHARMACEUTICALS may be of interest to investors who are looking for investments with a steady cash flow and a low return on investment. It has an intermediate health score of 4/10, indicating that it is likely to sustain future operations in times of crisis. Its primary strength lies in its asset base, so investors may want to consider investing if that is their focus. More…
Peers
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. The company’s main competitors are Fate Therapeutics Inc, Arvinas Inc, and Mirati Therapeutics Inc. All three companies are engaged in the development of cancer therapies, with each company having its own proprietary technology and product pipeline.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company’s immunotherapies are based on its proprietary platform of induced pluripotent stem cells (iPSCs). Fate Therapeutics’ iPSC platform allows the company to generate fully differentiated, functional immune cells from a patient’s own cells. These immune cells can then be used to treat the patient’s disease. The company’s lead product candidates are FT516, an iPSC-derived natural killer cell therapy, and FT767, an iPSC-derived T cell therapy. Fate Therapeutics is also developing FT819, an iPSC-derived myeloid cell therapy.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 2.35B as of 2022 and a Return on Equity of -20.23%. Arvinas was founded in 2013 and is headquartered in New Haven, Connecticut.
– Mirati Therapeutics Inc ($NASDAQ:MRTX)
Mirati Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics to treat cancer. The company’s market cap as of 2022 is 3.7B and its ROE is -33.77%. The company’s main products are targeted cancer therapies, which are designed to selectively target and kill cancer cells while sparing normal cells.
Summary
Syndax Pharmaceuticals, Inc. has seen its stock price move up after brokerages gave it an average rating of “Buy”. This positive sentiment is likely due to the company’s strong performance and outlook. Analysts believe that the company has good potential for growth and financial stability. They also highlight the company’s robust product pipeline, which includes treatments for cancer and other diseases.
This positive outlook makes the stock an attractive option for investors looking for long-term gains. Investors should take into account the risks associated with investing in Syndax Pharmaceuticals, Inc., including market volatility and potential regulatory changes.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
